Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
12
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
12
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
cancer
nonalcoholic steatohepatitis
cancer immunotherapy
clinical trials
deals
europe blog main
europe top stories
gene therapy
gilead sciences
glaxosmithkline
immunotherapy
loxo oncology
What
cancer
12
×
roundup
bio
drug
annual
clinical
medical
medicine
oncology
society
ahead
amid
bombast
cash
caught
conference
coronavirus
days
debate
develop
discussion
efforts
esmo
european
major
meeting
meso’s
million
miss
new
pandemic
pfizer’s
presidential
promise
response
study
therapeutics
tiny
today
tuesday’s
Language
unset
Current search:
cancer
×
biotech
×
" seattle top stories "
×
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?